Abstract | BACKGROUND:
Antibodies to the Rho GTPase-activating protein 26 (ARHGAP26, GRAF1) (also termed anti-Ca) were first described in patients with cerebellar ataxia. However, ARHGAP26 is also expressed in some hippocampal neurons. Moreover, some of the previously reported patients showed cognitive and affective symptoms. It is unknown whether those symptoms reflected involvement of the limbic system or were part of the so-called cerebellar cognitive/affective syndrome. CASE REPORT: CONCLUSION: This case indicates that the clinical spectrum of ARHGAP26-related autoimmunity might be broader than expected. Studies on the prevalence of anti-Ca/ARHGAP26 in patients with suspected limbic encephalitis seem warranted.
|
Authors | S Jarius, B Wildemann, W Stöcker, A Moser, K P Wandinger |
Journal | Journal of neuroimmunology
(J Neuroimmunol)
Vol. 286
Pg. 79-82
(Sep 15 2015)
ISSN: 1872-8421 [Electronic] Netherlands |
PMID | 26298328
(Publication Type: Case Reports, Journal Article)
|
Copyright | Copyright © 2015. Published by Elsevier B.V. |
Chemical References |
- ARHGAP26 protein, human
- Antibodies
- Antipsychotic Agents
- GTPase-Activating Proteins
- Immunoglobulins
- Potassium Channels, Voltage-Gated
- Risperidone
- Diazepam
- Calcium
|
Topics |
- Adult
- Antibodies
(metabolism)
- Antipsychotic Agents
(therapeutic use)
- Calcium
(metabolism)
- Cerebellum
(metabolism)
- Diazepam
(therapeutic use)
- Female
- GTPase-Activating Proteins
(immunology)
- Hippocampus
(metabolism)
- Humans
- Immunoglobulins
(therapeutic use)
- Potassium Channels, Voltage-Gated
(immunology)
- Psychotic Disorders
(drug therapy, genetics, metabolism, pathology)
- Risperidone
(therapeutic use)
|